möglich sobald  bei der ZB eingereicht worden ist.
		
    Age-dependent impact of the major common genetic risk factor for COVID-19 on severity and mortality.
        
        J. Clin. Invest. 131:e152386 (2021)
    
    
    
				BACKGROUND: There is considerable variability in COVID-19 outcomes amongst younger adults-and some of this variation may be due to genetic predisposition. METHODS: We combined individual level data from 13,888 COVID-19 patients (N=7,185 hospitalized) from 17 cohorts in nine countries to assess the association of the major common COVID-19 genetic risk factor (chromosome 3 locus tagged by rs10490770) with mortality, COVID-19-related complications and laboratory values. We next performed meta-analyses using FinnGen and the Columbia University COVID-19 Biobank. RESULTS: We found that rs10490770 risk allele carriers experienced an increased risk of all-cause mortality (HR 1.4, 95%CI 1.2-1.7). Risk allele carriers had increased odds of several COVID-19 complications: severe respiratory failure (OR 2.1, 95%CI 1.6-2.6), venous thromboembolism (OR 1.7, 95%CI 1.2-2.4), and hepatic injury (OR 1.5, 95%CI 1.2-2.0). Risk allele carriers ≤60 years had higher odds of death or severe respiratory failure (OR 2.7, 95%CI 1.8-3.9) compared to those >60 years (OR 1.5, 95%CI 1.2-1.8, interaction-p=0.038). Amongst individuals ≤60 years who died or experienced severe respiratory failure, 32.3% were risk variant carriers, compared to 13.9% of those not experiencing these outcomes. The genetic risk improved the prediction of death or severe respiratory failure similarly to, or better than, most established clinical risk factors. CONCLUSIONS: The major common COVID-19 genetic risk factor is associated with increased risks of morbidity and mortality, which are more pronounced amongst individuals ≤60 years. The effect was similar in magnitude and more common than most established clinical risk factors, suggesting potential implications for future clinical risk management.
			
			
		Impact Factor
					Scopus SNIP
					Web of Science
Times Cited
					Times Cited
Scopus
Cited By
					
					Cited By
Altmetric
					
				14.808
					0.000
					5
					12
					
					
				Anmerkungen
				
					
						 
						
					
				
			
				
			
				Besondere Publikation
				
					
						 
					
				
			
			
			
				Auf Hompepage verbergern
				
					
						 
					
				
			
			
        Publikationstyp
        Artikel: Journalartikel
    
 
    
        Dokumenttyp
        Wissenschaftlicher Artikel
    
 
     
    
    
        Schlagwörter
        Covid-19 ; Genetic Variation ; Genetics; Vaccine
    
 
     
    
    
        Sprache
        englisch
    
 
    
        Veröffentlichungsjahr
        2021
    
 
     
    
        HGF-Berichtsjahr
        2021
    
 
    
    
        ISSN (print) / ISBN
        0021-9738
    
 
    
        e-ISSN
        1558-8238
    
 
     
     
     
	     
	 
	 
    
        Zeitschrift
        Journal of Clinical Investigation
    
 
		
    
        Quellenangaben
        
	    Band: 131,  
	    Heft: 23,  
	    
	    Artikelnummer: e152386 
	    
	
    
 
  
         
        
            Verlag
            American Society of Clinical Investigation
        
 
        
            Verlagsort
            2015 Manchester Rd, Ann Arbor, Mi 48104 Usa
        
 
	
         
         
         
         
         
	
         
         
         
    
         
         
         
         
         
         
         
    
        Begutachtungsstatus
        Peer reviewed
    
 
    
        Institut(e)
        Institute of Virology (VIRO)
    
 
    
        POF Topic(s)
        30203 - Molecular Targets and Therapies
    
 
    
        Forschungsfeld(er)
        Immune Response and Infection
    
 
    
        PSP-Element(e)
        G-502700-003
    
 
    
        Förderungen
        Amyndas Pharmaceuticals
    
 
     	
    
    
        WOS ID
        WOS:000726717300012
    
    
        PubMed ID
        34597274
    
    
        Erfassungsdatum
        2021-11-24